Language selection

Search


Guidance on post-notice of compliance changes : overall quality document for biologic and Schedule C drugs for human use.H164-424/2026E-PDF

"This guidance document applies to sponsors intending to make changes to drugs that have received a NOC pursuant to Section C.08.004 of the Food and Drug Regulations, that are biologics and Schedule C drugs (radiopharmaceuticals and cold kits) for human use including those submissions for which a NOC has been recommended but the issuance of the NOC has been placed on hold"--page 1.

Permanent link to this Catalogue record:
publications.gc.ca/pub?id=9.961955&sl=0

Publication information
Department/Agency
  • Canada. Health Canada, issuing body.
TitleGuidance on post-notice of compliance changes : overall quality document for biologic and Schedule C drugs for human use.
Publication typeMonograph
Language[English]
Other language editions[French]
FormatDigital text
Electronic document
Note(s)
  • Issued also in French under title: Ligne directrice sur les changements survenus après l'avis de conformité : document de synthèse sur la qualité pour les médicaments biologiques et les médicaments de l'annexe C destinés à l'usage humain.
Publishing information
  • ©2026
  • Ottawa : Health Canada = Santé Canada, May 15, 2026.
Description1 online resource (ii, 26 pages)
ISBN9780660995779
Catalogue number
  • H164-424/2026E-PDF
Departmental catalogue number260041
Subject terms
Request alternate formats
To request an alternate format of a publication, complete the Government of Canada Publications email form. Use the form’s “question or comment” field to specify the requested publication.

Page details